If one of their customers can get approval for their process then there will be a move up. BLFS claimed this would likely happen by the end of this year.
"I should remind you that a majority of the immunotherapy companies conducting clinical trials of CAR-T and other T-cells to treat and potentially cure patients with blood cancers and solid tumors use our products to preserve the starting material and/or final manufactured cell products.
We believe our annual revenue opportunity for a typical cell therapy candidate if approved, ranges from $500,000 to $2 million. In the first quarter of 2017, we gained 36 new direct customers, including first time direct orders from 20 new regenerative medicine customers."
They need to get the ball rolling with one.
News 
Market Data 
Discover 
